3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Recurrence
1
Melanoma
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Lymphoma, B-Cell, Marginal Zone
1
Lung Neoplasms
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Glioma
1
Diffuse Intrinsic Pontine Glioma
1
Central Nervous System Neoplasms
1
Carcinoma, Squamous Cell
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Rituximab
23
Lenalidomide
11
Cyclophosphamide
10
zanubrutinib
9
Bendamustine Hydrochloride
8
venetoclax
6
ibrutinib
6
fludarabine
6
parsaclisib
5
idelalisib
5
ublituximab
4
obinutuzumab
4
aflibercept
4
Prednisone
4
pirtobrutinib
3
Vincristine
3
ME-401
3
Doxorubicin
3
umbralisib
2
tazemetostat
2
marizomib
2
epratuzumab
2
Radioimmunodetection
2
voruciclib
1
veltuzumab
1
varlilumab
1
tislelizumab
1
tetulomab tetraxetan lu-177
1
tafasitamab
1
repaglinide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Lymphoma, B-Cell, Marginal Zone
×
Maintenance
×
Clear all
NCT04542824
2026-06-02
EPCOREâ„¢ NHL-3
Genmab
Phase 1/2
Active not recruiting
78 enrolled